---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-001984"
form_type: "8-K"
ticker: "ZURA"
cik: "0001855644"
company_name: "Zura Bio Ltd"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:35:22.291086+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Zura Bio appoints Robert Lisicki as President/COO and Kiran Nistala as CMO; CMO Chris Cabell departs

## Summary
- Chris Cabell steps down as Chief Medical Officer and EVP effective Jan 15, 2024; no disagreement with management.
- Robert Lisicki appointed President and COO effective Jan 8; base salary $440,000 with 40% target bonus and 1M options grant.
- Kiran Nistala joins as EVP Development and CMO; previously VP Immunology at AstraZeneca and roles at GSK.
- Lisicki brings experience from Arena Pharmaceuticals (acquired by Pfizer) and Regeneron; Nistala from GSK and AstraZeneca.
- Leadership hires position Zura Bio for Phase 2 clinical trial readiness across multiple indications in 2024.

## SEC filing metadata
- accession: 0001104659-24-001984
- form_type: 8-K
- ticker: ZURA
- cik: 0001855644
- company_name: Zura Bio Ltd
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855644/000110465924001984/0001104659-24-001984-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855644/000110465924001984/tm242343d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-001984
- JSON: https://secwatch.observer/filing/0001104659-24-001984.json
- Plain text: https://secwatch.observer/filing/0001104659-24-001984.txt

## Key facts
- Executive change
  Robert Lisicki was appointed as President and Chief Operating Officer at Zura Bio Ltd.
  - Action: appointed
  - Role: President and Chief Operating Officer
  source text: On January 3, 2024, the Company appointed Mr. Robert Lisicki as President and Chief Operating Officer, effective as of January 8, 2024 (the “Commencement Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855644/000110465924001984/0001104659-24-001984-index.htm
- Executive change
  Chris Cabell departed as Chief Medical Officer and Executive Vice President at Zura Bio Ltd.
  - Action: stepping down
  - Role: Chief Medical Officer and Executive Vice President
  source text: On January 4, 2024, Dr. Chris Cabell and Zura Bio Limited (the “Company”) agreed that he will be stepping down as the Company’s Chief Medical Officer and Executive Vice President, effective on January 15, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855644/000110465924001984/0001104659-24-001984-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.